Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Allergies
Inspire to Discontinue Development of Epinastine Nasal Spray
May 9th, 2008
Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced that its Phase 3 trial with epinastine nasal spray for the treatment of seasonal allergic rhinitis (SAR) did not meet its primary endpoint. "Our analysis of the overall data in this program and the current competitive environment in allergic rhinitis indicate that epinastine nasal spray does not show potential to meet our desired product profile in the United States," stated Christy L. Shaffer, Ph.D., President and CEO of Inspire. "We do not plan to allocate any future resources to this program and will focus on our commercial products and progressing our high-priority development programs." The...
Source: Health Business Week (2008-05-09)
|
